Andrew Miller, MD
Colon & Rectal Surgery · Austin, TXNPI 1639438070
Payments from drug & device makers
What this record shows
This record is dominated by education: $35,750 of the $41,170 with a category attached, or 86.8%. Intuitive Surgical accounts for 94.3% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $29,558 and has fallen 96.3% since, to $1,087 in 2025.
Across 200 payments — averaging $205.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$39K
- Zyla Life Sciences, Inc.$634
- Medtronic$458
- TELA Bio, Inc.$158
- Axonics, Inc.$127
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$126
- plus $828 from 18 others
What the payments were for
- Speaking & faculty fees$5001%
- Travel & lodging$1,8885%
- Food & beverage$3,0327%
- Education$35,75087%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 48 | $38,839 |
| Zyla Life Sciences, Inc. | 78 | $634 |
| Medtronic(2 entities) | 14 | $458 |
| TELA Bio, Inc. | 8 | $158 |
| Axonics, Inc. | 5 | $127 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $126 |
| Davol Inc. | 5 | $118 |
| Johnson & Johnson | 5 | $104 |
| Baxter Healthcare | 4 | $93 |
| Integra Lifesciences Corporation | 4 | $84 |
| Pacira Pharmaceuticals Incorporated | 2 | $54 |
| Edwards Lifesciences | 2 | $49 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $49 |
| Innovation Technologies Inc | 2 | $44 |
| Romark Laboratories, LC | 3 | $40 |
| Conmed Corporation | 2 | $29 |
| Kerecis Limited | 1 | $29 |
| Dilon Technologies, Inc. | 1 | $28 |
| THD America, Inc. | 1 | $23 |
| Covidien LP | 1 | $22 |
| Medspira, LLC | 1 | $20 |
| Heron Therapeutics, Inc. | 1 | $17 |
| Redhill Biopharma Inc. | 1 | $14 |
| Acell, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$38,262
How this compares
$41,170 in reported general payments places this provider in the 85th percentile of 200 colon & rectal surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Neomycin Sulfate | 43 | $207 |
| Gabapentin | 49 | $155 |
| Metronidazole | 48 | $68 |
| Tramadol Hcl | 27 | $47 |
Paid to pharmacies, not to this prescriber.
Other colon & rectal surgery in Austin
- Thiru LakshmanAustin$756K
- Amar ShahAustin$51K
- Megan TurleyAustin$21K
- Ricardo SolisAustin$15K
- Diego Marines CopadoHouston$462K
- Bidhan DasSugar Land$350K
- Christopher de JesusSan Antonio$201K
- Farshid AraghizadehFort Worth$181K
- Jefferson HurleyIrving$163K
- Erik AskenasyHouston$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.